Objective: The value of follow-up after treatment for endometrial cancer will be discussed. Study design: We evaluated our clinical experience, including mode of detection, of patients with recurrent endometrial cancer treated in the Erasmus Medical Centre in Rotterdam over a 20-year period. Clinical data and histopathological features from 64 patients were analyzed. Survival was analyzed with a Kaplan-Meier curve. Results: Twenty-two patients had a local recurrence, 30 had a distant recurrence and 12 had simultaneous local and distant recurrent disease. Ninety-five percent of the local recurrences and 67% of the distant recurrences were detected within three years. Twenty-seven patients had a screen-detected recurrence, 34 had an interval screening recurrence and two had a chance finding recurrence. The overall survival rate at two years was 70% and at five years 53%. Patients with a screen-detected recurrence had a 5-year survival rate of 62%, while patients with interval screening and chance finding recurrences had a 5-year survival rate of 47%. Conclusion: A follow-up program in the first three years after primary treatment of endometrial cancer is useful in detecting recurrent disease. We have no reason to use a different program of follow-up in patients with low risk primary disease.

, , , ,
doi.org/10.1016/j.ejogrb.2005.12.014, hdl.handle.net/1765/36150
European Journal of Obstetrics & Gynecology and Reproductive Biology
Erasmus MC: University Medical Center Rotterdam

van Wijk, H., Huikeshoven, F., Abdulkadir, L., Ewing, P., & Burger, C. (2007). Recurrent endometrial cancer: A retrospective study. European Journal of Obstetrics & Gynecology and Reproductive Biology, 130(1), 114–120. doi:10.1016/j.ejogrb.2005.12.014